O
pioid overdoses continue to increase in many areas across the United States, despite substantial attention from federal and state governments, public health authorities, and health care systems (1) . Reversing this trend requires a robust mental health and addiction treatment infrastructure to provide access to evidence-based treatment, such as methadone or buprenorphine (2) (3) (4) . However, the vast majority of persons with opioid use disorder (OUD) have not received treatment in the past year (5) . Although access to OUD treatment is a challenge for many patients, little is understood about the diverse barriers they encounter in seeking treatment, which may include lack of appointment availability, long wait times, or high costs.
Outpatient treatment with different formulations of buprenorphine-naloxone ("buprenorphine") is a particularly promising approach to expand access to OUD treatment. Buprenorphine may be prescribed in officebased settings or outpatient treatment programs and is associated with substantial reductions in overdose deaths and all-cause mortality and a greater likelihood of successful long-term recovery (6 -8) . Buprenorphine prescribed through an outpatient office has great capacity to serve the unmet demand for OUD treatment, but the availability of prescribers is limited. Many clinicians have little experience with buprenorphine, because training in addiction medicine in medical school and residency often is minimal (9) . Further, to prescribe buprenorphine, providers must obtain a federal waiver, which requires hours of formal training: 8 for physicians and 24 for nurse practitioners and physician assistants. Even with a waiver, clinicians have a cap on the number of patients they can treat with buprenorphine at any time (10 -13) . Fewer than 6% of physicians, 2% of nurse practitioners, and 1% of physician assistants (14) nationally have a waiver (15) , and many buprenorphinewaivered clinicians are not actively prescribing (16, 17) .
Although the limited supply of prescribers contributes to the underutilization of buprenorphine, many other barriers may exist between a person's decision to seek treatment and his or her success in obtaining an appointment. Understanding the nature of these patient-facing barriers is crucial to designing effective policy. For example, potential interventions might dif-fer, depending on whether a key barrier to treatment access is the percentage of clinicians taking new patients, long wait times, or lack of appointment acceptance for subgroups disproportionately affected by OUD, such as Medicaid enrollees and uninsured persons (18) . Other practices charge substantial fees for uninsured patients paying cash or supplemental expenses for such services as urine drug tests (19) , which may be an additional barrier for many.
Beyond acceptance of new patients, prompt initiation of buprenorphine (a clinically supervised process referred to as "induction" that may take place in the office or at home) (20, 21) is another important factor in accessing care, because every day without treatment carries an elevated risk for escalating opioid use and overdose (22) (23) (24) . Patients must be in active opioid withdrawal to initiate buprenorphine treatment safely, which makes the timing of induction critical. Outcomes are better when induction is offered as soon as possible (24, 25) , but many clinicians have specific requirements for patients to meet before offering them buprenorphine, such as active engagement in counseling, which may result in delays (26) .
To examine buprenorphine treatment barriers from the patient perspective, we performed an audit ("secret shopper") study of publicly listed buprenorphine clinicians in states with the highest opioid overdose mortality rates nationally in 2016, posing as callers with either Medicaid coverage or without insurance and paying cash.
METHODS

Study Design
We used audit methods simulating a standard OUD presentation to minimize social desirability and recall biases common in traditional surveys (27) . To assess access, wait times, and out-of-pocket costs, callers posed as 2 identical patients reporting active heroin use and seeking buprenorphine treatment: 1 with Medicaid coverage and the other without insurance and self-paying.
Study Population and Sample Selection
To define the sample frame of buprenorphinewaivered clinicians for selection, we obtained all data available from the public Buprenorphine Practitioner Locator Web site (28) , updated daily by the federal Substance Abuse and Mental Health Services Administration. Clinicians may opt to be publicly listed on this Web site after receiving a waiver: In the data used for this study, 54% of waivered clinicians nationally were listed (28, 29) . We focused on sampling publicly listed clinicians, because they are the providers most easily found by real patients seeking treatment without a referral. The Practitioner Locator Web site lists buprenorphine clinicians by name, degree, clinic phone number, and address (28) . We captured Practitioner Locator data in January 2018 (for physicians) and June 2018 (for nurse practitioners and physician assistants). In addition, we obtained the buprenorphine waiver patient cap for each clinician (a maximum of 30, 100, or 275 patients certified for treatment at any time ["waiver capacity"]), as well as the year of his or her first waiver, through a Freedom of Information Act request to the Substance Abuse and Mental Health Services Administration. We classified clinics as urban or rural by using the Rural-Urban Commuting Area Code classification system from the University of Washington Rural Health Research Center (30) .
From this national database, we sampled publicly listed clinicians from 6 jurisdictions (referred to as "states" going forward) with the highest opioid-related overdose mortality rate in 2016 (31): Massachusetts, Ohio, Maryland, West Virginia, New Hampshire, and the District of Columbia. We took random samples of buprenorphine clinicians with a unique phone number and address combination in each state to obtain a targeted sample of 1050 clinicians. In 3 states with fewer than 250 listed buprenorphine clinicians (West Virginia, New Hampshire, and the District of Columbia), we sampled all listed clinicians, whereas in states with more than 250 listed buprenorphine clinicians (Ohio, Massachusetts, and Maryland), we sampled 250 clinicians stratified by waiver capacity to evenly divide each state's sample between low-waiver capacity (30-patient cap) and high-waiver capacity (100-or 275-patient cap) clinicians.
The Harvard T.H. Chan School of Public Health Institutional Review Board did not deem our analysis to be human subjects research.
Data Collection
Two trained female research assistants called clinicians at their publicly listed phone number from July through November 2018. The callers used a standardized script that simulated a 30-year-old, otherwisehealthy woman who was actively using heroin and seeking to start buprenorphine-naloxone treatment (for the full script, see the Supplement, available at Annals .org). The script was designed to represent a plausible presentation of a person with OUD without comorbid psychiatric or medical conditions. Two different scripts were used to simulate patients with identical clinical histories and demographic characteristics: 1 insured by Medicaid and 1 uninsured and willing to pay with cash ("uninsured-self-pay"). These 2 scenarios were chosen because these 2 groups are disproportionately affected by OUD (32) , and no clinical reason exists for them to receive different treatment.
Clinicians were included in the final sample for analysis if a caller could contact a live scheduler within 3 separate attempts during business hours. If the sampled clinician was unavailable or not taking patients, the caller would attempt to make an appointment with any other buprenorphine prescriber available at the same clinic. A clinician was classified as a nonrespondent if a live scheduler was unreachable after 3 contact attempts and the clinician was not otherwise excluded as out of sample.
Clinicians were defined as out of sample (that is, not eligible as a potential respondent) if any of the ORIGINAL RESEARCH Access to Buprenorphine Treatment in Areas With High Opioid Death Rates following criteria were met: a wrong or nonworking phone number, no buprenorphine-prescribing clinicians at the number, or location in the wrong clinical or geographic setting for the script (such as a Veterans Affairs or out-of-state clinic). Some clinicians also were excluded from the sample if the caller was unable to provide verifiable information that real patients could provide, such as a Social Security number.
Each clinician in the sample was contacted by 2 separate callers using Medicaid or uninsured-self-pay scripts at least 4 weeks apart. Calls were made during normal business hours (9:00 a.m. to 12:00 p.m. and 1:00 p.m. to 5:00 p.m. local time). If a voicemail greeting on an unanswered call indicated that hours of operation deviated from the default, subsequent calls were made during the stated clinic hours and days of operation. For logistic reasons, the callers did not leave voicemail messages. All appointment requests were canceled before the end of each phone call.
Study Outcomes
The primary outcomes were appointment availability and wait time to initial appointment, with the key exposure of insurance type. Secondary outcomes were availability of an appointment with the possibility of in- † Clinicians who were eligible to be in our sample for telephone contact but were randomly not selected. ‡ Includes situations in which a real-world patient may have been able to get an appointment but the study patient could not, such as when personal identifying information beyond a date of birth and name (such as a Medicaid plan number) or voicemail was required to inquire about appointment availability. § Each clinician was called under 2 scenarios-a patient covered by Medicaid and an uninsured patient who was self-paying-represented by "contacts," such that there are 2 contacts for each clinician. We were able to contact 380 of the 546 in-sample clinicians twice, once by the Medicaid-insured caller and once by the uninsured-self-pay caller, and 89 clinics by only 1 of the callers (52 Medicaid, 37 uninsured-self-pay).
Access to Buprenorphine Treatment in Areas With High Opioid Death Rates ORIGINAL RESEARCH duction, overall wait time until induction, and the cost of treatment for the uninsured-self-pay patient. We captured whether an appointment was offered at any time in the future and the earliest available date for an appointment. If an appointment was not offered, we captured the reason an appointment was not available. Offers to be put on a waitlist were defined as "no appointment offered," because whether the patient could receive timely access to a clinician was uncertain. If an appointment was offered, we captured the number of days until the appointment from the date of the call and whether buprenorphine induction might be possible on the day of the first appointment. Clinicians who indicated that first-day induction was possible but contingent on the outcome of a clinical assessment were considered as "offering possible induction." If buprenorphine induction or prescription on the initial visit was not permitted (for example, if clinic policy prohibited buprenorphine from being prescribed or dispensed on the first encounter), we captured the estimated number of days between the initial appointment and induction. When an exact date for any of the outcomes could not be given but a range was provided (for instance, "a week or 2"), then an estimated date in the middle of the range was recorded. For the uninsured-self-pay script, the callers also obtained the cost that the clinic would charge up to induction and assessed whether extra charges for laboratory work, such as urine drug tests, were also expected.
Statistical Analysis
We stratified response rates at the clinician level by whether clinicians were never reached, reached by either the Medicaid or the uninsured-self-pay caller, or reached by both callers. Descriptive results were calculated for appointment and induction availability as well as wait time, stratified by the insurance status of contacts. In addition, we examined these outcomes across different clinician characteristics, including state and urban or rural location.
Role of the Funding Source
This project was supported in part by the National Institute on Drug Abuse. The funding sources had no role in the design or conduct of the study; collection, management, analysis, or interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication.
RESULTS
From the initial sample frame of 1076 clinicians in 6 states, 530 were excluded as out of sample (431 [81%] because they had invalid contact information or were inactive prescribers), leaving 546 clinicians, or 1092 paired contacts, in the sample (Figure) . We reached scheduling staff at least once within 3 attempts for 469 clinicians in 849 calls, resulting in a clinician-level response rate of 86%, or a contact-level response rate of 78%. Most clinician respondents (n = 380) had 2 paired contacts, whereas 89 clinicians could be reached only once (Figure) . Contacts were less likely to have a response if the clinician carried a 30-patient capacity waiver versus a 100-or 275-patient capacity waiver and if the practice was in a rural versus an urban setting ( Table 1) . Overall, response rates for Medicaid and uninsured-self-pay contacts were similar ( Table 2 ). In 210 of the 243 contacts (86%) that were classified as nonrespondents, every call attempt ended in the caller being sent to voicemail.
Appointment Availability and Wait Time
An appointment was offered in 233 of 432 contacts (54%) by the Medicaid caller and 258 of 417 (62%) by the uninsured-self-pay caller ( Table 3) . Appointments were refused most commonly because the clinician was not accepting patients with the caller's insurance status (44% of contacts with no appointment), not accepting new patients (36% of contacts with no appointment), or waitlisting patients (17% of contacts with no appointment) (Appendix Table 1 , available at Annals.org). However, these reasons varied by state; for example, 44% of denied appointments were because of waitlisting in West Virginia and 8% in Maryland (Appendix Table 2, available at Annals.org). Among the 380 clinics reached by both the Medicaid and uninsured-self-pay callers, 156 (41%) offered appointments to both callers, 88 (23%) to neither caller, 83 (22%) to the uninsuredself-pay but not the Medicaid caller, and 53 (14%) to the Medicaid but not the uninsured-self-pay caller (Appendix Table 3 , available at Annals.org). 
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An appointment was offered to the Medicaid caller 70% of the time by advanced practice clinicians and 40%, 44%, and 59% of the time by physicians with 30-, 100-, and 275-patient waivers, respectively ( Table 4) . The uninsured-self-pay caller was offered an appointment 59% of the time by advanced practice physicians and 47%, 62%, and 72% of the time by physicians with 30-, 100-, and 275-patient waivers, respectively. Availability also varied between insurance categories in different states; for example, 31% of clinicians in Ohio and 10% in Massachusetts offered appointments to the uninsured-self-pay but not the Medicaid caller ( Table  5 ). Appointment availability in urban areas was 56% and 64% for Medicaid and uninsured-self-pay contacts, respectively, and 48% and 54% in rural areas ( Table 4) .
The median wait time to an initial appointment was 6 days (interquartile range [IQR], 2 to 10 days) for Medicaid contacts and 5 days for uninsured-self-pay contacts (IQR, 1 to 9 days) ( Table 4) .
Availability of Appointment With Possible Buprenorphine Induction
An appointment with the possibility of buprenorphine induction on the first visit was offered for 117 contacts from the Medicaid caller (50% of contacts with an appointment offered or 27% of all contacts [ Table  3 ]) and 169 from the uninsured-self-pay caller (66% of contacts with an appointment offered or 41% of all contacts).
Again, heterogeneity was found across states: 35% of clinicians in Ohio and 10% in Massachusetts offered an appointment with possible induction to the uninsured-self-pay but not the Medicaid caller ( Table  5) . Among the 380 clinics reached by both the Medicaid and uninsured-self-pay callers, 73 (19%) offered an appointment with possible induction to both callers, 191 (50%) to neither caller, 83 (22%) to the uninsuredself-pay but not the Medicaid caller, and 33 (9%) to the Medicaid but not the uninsured-self-pay caller (Appendix Table 3 ). Physicians with 30-patient waiver capacity offered appointments with possible induction to 15% and 18% of Medicaid and uninsured-self-pay callers, respectively. Physicians with 275-patient waiver capacity offered appointments with possible induction to 40% and 60% of Medicaid and uninsured-self-pay callers, respectively ( Table 4) .
Among the clinicians contacted, the median wait time from first contact to possible induction was 8 days (IQR, 4 to 15 days) for Medicaid contacts and 7 days (IQR, 3 to 14 days) for uninsured-self-pay contacts ( Table 4) .
Out-of-Pocket Costs
Of 417 clinicians contacted by the uninsured-selfpay caller, 242 (58%) provided estimates for the out-ofpocket fees charged until induction. The median cost was $250 (IQR, $180 to $350), with 19 providers (5%) estimating $500 or more until induction. In addition, 131 (54%) of the clinicians who provided cost estimates to the uninsured caller reported that additional fees would be charged for urine drug testing or other laboratory tests before induction.
DISCUSSION
In 6 states with the highest burden of opioid overdose mortality in the United States, 38% to 46% of callers who reported current heroin use were denied an appointment from a buprenorphine prescriber, and only 50% to 66% of clinicians booking a new appointment allowed buprenorphine induction at the first visit. A smaller percentage of callers with Medicaid coverage than those paying with cash were offered appointments. The rate of Medicaid appointment availability fell within the range seen in previous audit surveys performed in various settings (34% to 66% offered) (33) (34) (35) , as well as in recent, smaller, self-reported surveys 
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ORIGINAL RESEARCH of buprenorphine-waivered providers, which found that more than half of buprenorphine prescribers did not accept any insurance (17, 36) . This study builds on the existing literature on buprenorphine providers by using a multistate audit survey to directly assess access and by capturing the timing and availability of possible buprenorphine induction at the initial visit. An unexpected finding was that wait times were generally less than 1 to 2 weeks, suggesting that the most prominent barrier to buprenorphine access in this sample was the scarcity of clinicians accepting new patients. Given the high burden of opioid-related mortality in the states we surveyed, 38% and 46% of prescribers declining new uninsured-self-pay or Medicaid patients, respectively, may represent a substantial barrier for patients hoping to find a clinician rapidly. However, the appointment availability and wait times we observed for buprenorphine treatment were no worse than recent estimates for general primary care in other settings. For example, a 10-state survey in 2016 found that 48.5% of clinics declined new Medicaid patients (37), whereas a different 2017 study of private clinics in 30 metropolitan areas nationally found mean wait times of 40.7 days for new appointments (38) . The coexistence of many clinicians declining new patients and providers offering appointments with short wait times may reflect poor retention of patients in buprenorphine treatment, leaving treatment slots open for new patients. Beyond the number of clinicians declining new appointments, a substantial proportion of publicly listed clinicians were no longer prescribing or no longer at the listed phone number, further increasing the number of calls and time necessary for a patient to find a prescriber.
One encouraging sign is that the highest appointment success rates for the Medicaid calls were for advanced practice clinicians and physicians with a 275-patient waiver capacity, who are perhaps more likely to work in settings with a high volume of patients receiving buprenorphine treatment. The higher appointment success among clinicians using waivers enabled by the Comprehensive Addiction and Recovery Act, passed IQR = interquartile range; NP = nurse practitioner; PA = physician assistant. * In 157 cases, we were told that the provider of interest was not available and an alternative provider at the clinic would see the caller. In 79 of these cases, the alternative provider was identified in the Substance Abuse and Mental Health Administration database of publicly listed providers and the alternative clinician's credentials, waiver capacity, and years since initial waiver were used. The sampled clinician's characteristics were used in cases in which the alternative provider could not be identified. † Each of 469 clinicians was contacted at least once with Medicaid or uninsured-self-pay scripts; 380 clinicians had 2 responses, and 89 could be contacted only once. See Figure 1 for the cohort flow. ‡ Wait time is expressed as the number of days from the contact until the earliest anticipated first appointment for the "any appointment" outcome. For the "appointment with possible induction" rows, the wait time is the number of days from contact until the earliest anticipated date of possible induction with buprenorphine. § Includes physicians only, because advanced-level practitioners had been permitted to receive a waiver under the Comprehensive Addiction and Recovery Act of 2016 <2 y before the calls were made.
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by Congress in 2016, suggests that the policy changes creating these new waiver categories (39, 40) have promise for expanding treatment access. Few clinicians offered the possibility of buprenorphine induction at the first visit. Providers may have practical reasons for delaying induction; for example, they may want to complete a full assessment before prescribing buprenorphine to avoid adverse outcomes. However, many patients with active OUD might easily be lost to follow-up without rapid induction, exposing them to a higher risk for overdose and other adverse outcomes (22) (23) (24) (25) . This represents an additional barrier preventing patients with OUD from receiving treatment. Previous research found that the mortality risk for persons with OUD waiting to start methadone treatment is 10 times greater than for those who initiate treatment, highlighting potentially great risk for delaying medication initiation (41) .
Regardless of clinician preference, no clinical justification exists for Medicaid patients to have less opportunity for rapid buprenorphine induction than persons with other types of coverage. The disparity we found with Medicaid callers might reflect poor coverage or additional administrative hurdles, such as the requirement by many Medicaid programs for prior authorization to prescribe buprenorphine (42) . Our findings suggest that efforts to expand access to buprenorphine treatment should explicitly consider availability of and time to induction, as well as disparities in these measures across populations.
Patients without insurance also had cost barriers that were consistent across all 6 states in our sample. Half of the clinicians accepting uninsured patients charged $250 or more, with several clinics asking over $500. Perhaps even more important is that many clinicians required additional fees for laboratory or urine studies, which might accumulate into hundreds of additional dollars for testing (19) . These costs may represent meaningful barriers for persons seeking treatment for substance use disorder, 60% of whom lived below 200% of the federal poverty limit in 2017 (43) .
This study has several limitations. First, our survey included only 5 states and the District of Columbia, all of which have large numbers of buprenorphine providers per capita and expanded Medicaid eligibility after the Patient Protection and Affordable Care Act was passed. Therefore, our results may not generalize to U.S. regions without these characteristics. However, we chose these 6 states because they arguably have the greatest urgency to address access nationally, given their elevated opioid-related mortality rates. Second, we could survey only publicly listed outpatient buprenorphine clinicians; including nonlisted clinicians may have changed our estimates. Approximately half of buprenorphine prescribers were not listed (28) , which limits the generalizability of our sample. In addition, many patients probably seek buprenorphine prescribers through informal channels, such as word of mouth. Therefore, this study should be interpreted as an audit of the publicly listed subset of providers, not all buprenorphine prescribers. We also lacked detailed information on the nature of the practices of buprenorphine providers (for example, primary care clinic vs. specialized addiction treatment), which might influence the interpretation of our results. Our measures of access also may have been biased by the nature of our survey methods and script, which necessarily could capture only 1 common clinical scenario. We could not leave voicemail messages, which excluded from our sample some clinicians who otherwise may have offered appointments. In addition, schedulers may not have known exactly when induction would take place, because several factors may be involved in making this decision; therefore, induction wait times should be interpreted as estimates. Finally, our sample size may have limited our ability to capture small but clinically relevant differences in outcomes among subgroups, particularly across states. However, to our knowledge, this is the largest audit study to date focused on OUD treatment.
In conclusion, our audit study found that many publicly listed buprenorphine prescribers in states with a high OUD-related mortality rate were not accepting new patients. Nevertheless, among those who were accepting new patients, wait times were not long, suggesting an underused capacity for buprenorphine 
